9 February 2018 - It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.

NICE is sticking with its decision not to recommend the drug’s use to treat liver cancer that has spread around the body, is inoperable and has previously been treated with the drug, sorafenib.

Sorafenib is given to liver cancer patients as a first line of attack, but for those who cannot tolerate the drug, or do not respond to it, the only other option is best supportive care.

Read Pharma Times article